Our research is based on sources that we believe to be reliable. According to analyst projections, CRSP’s forecast low is $45 with $210 as the target high. Investing involves substantial risk. You can cancel your subscription at any time without any cost. AIStockFinder is a company specialized in predictive algorithms. GOOS Menu. CRISPR Therapeutics AG (CRSP) estimates and forecasts Financhill is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. WMS The risk involved with trading stocks, options and other securities is not suitable for all investors. Please contact your financial advisor for specific financial advice tailored to your personal circumstances. CRISPR Therapeutics Stock Forecast. APPS Further, owners, employees, agents or representatives of Financhill are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory. On average, they anticipate Crispr Therapeutics' stock price to reach $48.9167 in the next twelve months. GME Disclaimer: Past performance is no guarantee of future performance. But CRISPR Therapeutics could also have another product on the market in 10 years. In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. We expect investors to focus on CRISPR Therapeutics AG ’s CRSP progress with its lead gene-editing candidate CTX001 and other pipeline candidates when it reports fourth-quarter and full-year 2020 ... CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2020. The CRISPR Therapeutics AG stock price fell by -3.29% on the last day (Wednesday, 27th Jan 2021) from $169.53 to $163.95. If you had invested in CRISPR Therapeutics AG stock at $14.09, your return over the last 4 years would have been 1,075.87%, for an annualized return of 85.18%. Practical application of the products herein are at your own risk and Financhill.com, its partners, representatives and employees assume no responsibility or liability for any use or mis-use of the product. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. CRISPR Therapeutics AG (CRSP) projections and forecasts Get the latest CRISPR Therapeutics (CRSP) stock price quote with real-time news, financials, charts and other important investing information. While there’s a lot to be optimistic about when it comes to CRISPR Therapeutics stock, there’s also enough to give investors some pause as well, mainly the possibility that its flagship CTX001 treatment will fail. The average price target represents a -5.65% decrease from the last price of $164.50. In order for the stock price to hit the forecast high, the stock would need to surge +24.15% from its current level, while the stock would need to crash -73.4% from its current level to reach the projected low. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. stock was originally listed at a price of $14.09 in Oct 19, 2016. Trending Stocks: Dec. 4, 2017 Price forecast | 2 weeks: -0.46% | 1 month: -0.14% | 3 months: -0.73%. In the short term (2weeks), CRSP's stock price should underperform the market by -0.46%. The risk of loss in trading securities can be substantial. As of 2021 February 02, Tuesday current price of CRSP stock is 165.330$ and our data indicates that the asset price has been stagnating for the past 1 year (or since its inception).. CRISPR Therapeutics AG has been showing a declining tendency so we believe that similar market segments were mildly popular in the given time frame. Prices shown are actual historical values and are not adjusted for either splits or dividends. None of the information presented should be construed as an offer to sell or buy any particular security. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. SAVA Trading stocks, options and other securities involves risk. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. The price has fallen in 7 of the last 10 days and is down by -13.86% for this period. See CRISPR Therapeutics AG (CRSP) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. This product is for educational purposes only. CRISPR Therapeutics AG Stock Price Forecast, "CRSP" Predictons for2021 During that period the price should oscillate between … I confirm my subscription to AIStockFinder's newsletter. ET by Tomi Kilgore Crisper Therapeutics shares decline on … Price Target. Each premium signal is sent to all our premium users by mail. During the day the stock fluctuated 11.09% from a day low at $155.28 to a day high of $172.50. Close price at the end of the last trading day (Tuesday, 26th Jan 2021) of the CRSP … On its last earning announcement, the company reported a profit of 0.95$ per share. Get the latest Crispr Therapeutics earnings report, revenues as well as upcoming CRSP earnings dates, historical financial reports, news, analysis & more. CRISPR Stock Forecast: Genome editing has passed from science fiction to science fact. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Further, we expressly disclaim any responsibility to update such research. View today's stock price, news and analysis for CRISPR Therapeutics AG (CRSP). Any trades shown are hypothetical example and do not represent actual trades. The Investor Relations website contains information about CRISPR Therapeutics's business for stockholders, potential investors, and financial analysts. All Rights Reserved. and has now fallen 4 days in a row. The content on any of Financhill websites, products or communication is for educational purposes only. There is no one analyst in which a Quantitative Star Rating and Fair Value Estimate is attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., is responsible ... CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the a. Mr. Drouet brings more than 20 ... Feb. 01, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on ... Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned ... Unsure of the value of our premium account? 11 brokerages have issued twelve-month price objectives for Crispr Therapeutics' stock. Actual results may differ. We use our expertise to forecast stock prices. Nothing here in constitutes a recommendation respecting the particular security illustrated. The high price target for CRSP is $210.00 and the low price target for CRSP is $31.00. CRISPR Therapeutics Stock Forecast. The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. CRISPR Therapeutics AG's earnings in 2020 is $19,578,000. Past performance is not a guarantee of future results, and a loss of original capital may occur. Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 97.8% based on the past 4 years of stock performance. © Their average twelve-month price target is $141.79, predicting that the stock has a possible downside of 15.80%. At the moment the company generates 289M USD in revenues. On average, 9 Wall Street analysts forecast CRSP's earnings for 2020 to be $-289,223,931, with the lowest CRSP earnings forecast at $-305,698,712, and the highest CRSP earnings forecast at $-252,613,307. Get CRISPR Therapeutics AG (CRSP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. CRISPR Therapeutics AG Stock Forecast. See: Characteristics and Risks of Standardized Options. CRISPR's stock more than doubled last year while Editas' gained a respectable 27%. AIStockFinder will not accept liability for any loss or damage, including without limitation to, any loss of profit, which may arise directly or indirectly from use of or reliance on such information. CRISPR Therapeutics AG has risen higher in 3 of those 4 years over the subsequent 52 week period, corresponding to a historical probability of 75 %. Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$. Find real-time CRSP - CRISPR Therapeutics AG stock quotes, company profile, news and forecasts from CNN Business. The company executives may have good odds in positioning the firm resources to exploit market volatility in February.The stock standard deviation of daily returns for 30 days investing horizon is currently 4.59. To hit the forecast high, the stock’s price needs a +11.41% upsurge from its current level, while the stock would need to tank -76.13% for it to hit the projected low. CRISPR Therapeutics AG. Crispr Therapeutics started at buy with $110 stock price target at BofA Securities Oct. 5, 2020 at 11:33 a.m. Take the temperature and try it for free during one month. As always, use your best judgment when investing. CSU, Used by many of the world's smartest investors, Seasonal Stock Forecasts, Stock Valuations, Predictive Stock Analytics and see the #1 stock for the next 7 days, Scan for stocks set to soar and crash based on powerful seasonal trends plus view the stock with the most powerful seasonal trend this week, For Dividend Stocks, Blue Chip Stocks, Most Active Stocks, Most Shorted Stocks, Cheap Stocks, Stocks on Sale, and much more, Get new stock ideas every day delivered to your inbox based on income, stock ratings, seasonal trends, best value, and more, Gain full access to our most highly screened value stocks that even Buffett may approve. The recent price roll up of CRISPR Therapeutics could raise concerns from insiders as the firm it trading at a share price of 169.53 on 2,414,696 in volume. What this means: Crispr Therapeutics Ag (CRSP) gets an Overall Rank of 57, which is an above average rank under InvestorsObserver's stock ranking system. While our free users beat the market by 7% per quarter, last quarter, our premium users have beaten the market by 22%. Furthermore, CRISPR Therapeutics AG (CRSP)’s beta value is 2.36, and its average true range (ATR) is 12.74. The biotech plans to begin an early-stage clinical study … ... the average rating for CRSP stock is "Buy." Subscribe today to receive the latest AIStockFinder news via email. Invitae Stock Is Hot Right Now And Here’s Why It Will Only Get Hotter ... For the year, volumes grew 102% to 303,000 samples. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. between -16.76% and +21.47%. CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards? In the medium term (3months), CRSP's stock price should underperform the market by -0.73%. © AIStockFinder 2018. The average price target is $155.20 with a high forecast of $210.00 and a low forecast of $45.00. This suggests a possible upside of 27.2% from the stock's current price. Please see the "Historical Prices" tab for adjusted price values. Skip to content. You may unsubscribe from this service at any time. Add CRSP to your portfolio and optimize it! The stock's last reported lowest price was 160.37. Their forecasts range from $21.00 to $72.50. They don't need to monitor our website to act and trade optimally. Unlike free users, our premium users receive all forecasts, without any delay. Secure Your Limited Time Only Trial Access, Characteristics and Risks of Standardized Options. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. Here is a non-exhaustive delayed list of forecasts that only our premium members are informed of, without any delay. Our latest prediction for CRISPR Therapeutics AG's stock price was made on the Dec. 4, 2017 when the stock price was at 18.26$. In other news, VP Tony W. Ho sold 23,551 shares of the business’s stock in a transaction on Monday, December 21st. Get the latest CRISPR Therapeutics detailed stock quotes, stock trade data, stock price info, and performance analysis, including CRISPR investment advice, charts, stats and more. 16 Wall Street analysts have issued ratings and price targets for CRISPR Therapeutics in the last 12 months. Based on 13 analysts offering 12 month price targets for Crispr Therapeutics AG in the last 3 months. Over the next 52 weeks, CRISPR Therapeutics AG has on average historically risen by 97.8 % based on the past 4 years of stock performance. The Financhill.com educational training program and software services are provided to improve financial understanding. During that period the price should oscillate All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. CRISPR Therapeutics is selling at 165.70 as of the 31st of January 2021; that is -1.03 percent down since the beginning of the trading day. Equities research analysts forecast that CRISPR Therapeutics AG will post -4.97 earnings per share for the current fiscal year. The company’s stock has been forecasted to trade at an average price of $146.56 over the course of the next 52 weeks, with a low of $45 and a high of $210. View Analyst Price Targets for Crispr Therapeutics. Our first-in-class customer support provides our clients with timely responses to any trouble they might encounter.